Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 18, 2020BioScience TrendsOpen Access

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

View Full Paper
Ask AI
Bookmark
Share

Authors

JGJianjun GaoQingdao UniversityZTZhenxue TianQingdao UniversityXYXu YangHubei University of Arts and Science

Discussion

Loading...

Member takes

Implication

Multicenter clinical trials demonstrate efficacy and acceptable safety of chloroquine phosphate in COVID-19 pneumonia, suggesting utility as a repurposed antiviral agent.

Key Points

  • Evaluate the clinical efficacy and safety of chloroquine phosphate for the treatment of COVID-19 associated pneumonia.
  • Conducted multicenter clinical trials evaluating chloroquine phosphate across patient cohorts with COVID-19 associated pneumonia in China.
  • Demonstrated apparent clinical efficacy and acceptable safety against COVID-19 associated pneumonia compared to standard care pathways.
  • Informed national treatment recommendations for broader clinical use and guideline inclusion.

Cite This Study

Gao et al. (2020) studied this question.

synapsesocial.com/papers/69d88d5dc025a7c015bee043https://doi.org/10.5582/bst.2020.01047
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV2020 · 1,816 citations
  2. 2COVID-19 in the Cancer Patient2020 · 56 citations
  3. 3Drug treatment options for the 2019-new coronavirus (2019-nCoV)2020 · 1,191 citations
  4. 4Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro2020 · 7,407 citations